Jesse Alt Selected Research

Diazooxonorleucine

11/2019	Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
11/2019	Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.
10/2019	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
1/2019	JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress.
1/2019	Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders.
1/2017	N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.
9/2016	Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
4/2015	Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jesse Alt Research Topics

Disease

14	Neoplasms (Cancer) 04/2022 - 04/2015
5	Cognitive Dysfunction 11/2019 - 12/2012
4	Medulloblastoma 03/2022 - 10/2019
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2015
3	Pain (Aches) 01/2022 - 12/2012
3	Neurocognitive Disorders (Clerambault Syndrome) 09/2021 - 01/2017
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 12/2012
3	Neuralgia (Stump Neuralgia) 01/2017 - 12/2012
3	Schizophrenia (Dementia Praecox) 05/2016 - 12/2011
3	Vomiting 11/2010 - 08/2008
2	Rhabdoid Tumor (Rhabdoid Tumors) 04/2022 - 10/2019
2	Nervous System Diseases (Neurological Disorders) 01/2021 - 05/2019
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2020 - 01/2019
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2019 - 12/2012
2	Lymphoma (Lymphomas) 11/2019 - 12/2012
2	Mental Disorders (Mental Disorder) 10/2019 - 10/2017
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 07/2013
2	Neurobehavioral Manifestations 05/2016 - 01/2016
2	Nausea 11/2010 - 08/2008
1	Brain Injuries (Brain Injury) 12/2021
1	Geographic Atrophy 12/2021
1	Canavan Disease (Leukodystrophy, Spongiform) 01/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021
1	Obesity 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Rett Syndrome (Rett's Disorder) 01/2020
1	Neurofibrosarcoma (MPNST) 01/2020
1	Hypoxia (Hypoxemia) 11/2019
1	Acidosis 11/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2019
1	Anhedonia 01/2019
1	Glioma (Gliomas) 01/2019
1	Chronic Disease (Chronic Diseases) 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 09/2016
1	Psychotic Disorders (Schizoaffective Disorder) 01/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016

Drug/Important Bio-Agent (IBA)

16	Glutamine (L-Glutamine)FDA Link 03/2022 - 04/2015
10	ProdrugsIBA 01/2021 - 09/2016
9	Glutamic Acid (Glutamate)FDA Link 03/2022 - 07/2013
8	DiazooxonorleucineIBA 11/2019 - 04/2015
6	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)IBA 10/2019 - 12/2012
3	Mechanistic Target of Rapamycin Complex 1IBA 04/2022 - 01/2019
3	Glutathione (Reduced Glutathione)IBA 03/2022 - 01/2019
3	GlutaminaseIBA 01/2020 - 01/2016
3	Palonosetron (Aloxi)FDA Link 11/2010 - 08/2008
2	Amino Acids FDA Link 03/2022 - 01/2016
2	CarbonIBA 03/2022 - 01/2020
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 01/2019
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 12/2021 - 05/2019
2	JHU083IBA 09/2021 - 01/2019
2	purineIBA 01/2021 - 01/2020
2	JHU395IBA 01/2021 - 01/2020
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2019
2	EnzymesIBA 01/2021 - 05/2019
2	AcidsIBA 10/2019 - 12/2012
2	2-(phosphonomethyl)pentanedioic acidIBA 10/2017 - 03/2016
2	Analgesics (Analgesic Drugs)IBA 01/2017 - 12/2012
2	Serine (L-Serine)FDA Link 05/2016 - 12/2011
2	Pharmaceutical PreparationsIBA 03/2016 - 01/2016
1	sapanisertibIBA 04/2022
1	obatoclaxIBA 04/2022
1	Glucose (Dextrose)FDA LinkGeneric 03/2022
1	Tricarboxylic AcidsIBA 03/2022
1	HexosaminesIBA 03/2022
1	NucleotidesIBA 03/2022
1	Retinal Pigments (Pigments, Visual)IBA 12/2021
1	pyrenedodecanoylcarnitineIBA 12/2021
1	Ketotifen (Ketotifene)FDA Link 12/2021
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2021
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	EthoxyquinIBA 01/2021
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2021
1	Aspartic Acid (Aspartate)FDA Link 01/2021
1	Acetates (Acetic Acid Esters)FDA Link 01/2021
1	aspartate N-acetyltransferaseIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	phosphoribosyl-N-formylglycineamideIBA 01/2021
1	PlatinumIBA 01/2021
1	NitrogenIBA 01/2020
1	Dendrimers (Dendrons)IBA 01/2020
1	IsotopesIBA 01/2020
1	Lysine (L-Lysine)FDA Link 11/2019
1	Carboxylesterase (Hydrolase S)IBA 11/2019
1	CeramidesIBA 05/2019
1	Everolimus FDA Link 01/2019
1	GlucosinolatesIBA 01/2018
1	IsothiocyanatesIBA 01/2018
1	EstersIBA 01/2017
1	alkoxyl radicalIBA 01/2017
1	Alanine (L-Alanine)FDA Link 01/2016
1	Metformin (Glucophage)FDA LinkGeneric 01/2016
1	GlycogenIBA 01/2016
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2016
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2016
1	N-Methylaspartate (NMDA)IBA 01/2016

Therapy/Procedure

11	Therapeutics 04/2022 - 04/2015
5	Drug Therapy (Chemotherapy) 01/2021 - 08/2008
1	Immunotherapy 11/2019
1	Transplantation 01/2016